Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast 2024-2028

The global amyotrophic lateral sclerosis (ALS) treatment market size is estimated to grow by USD 663.7 million at a CAGR of 12.79% between 2023 and 2028. The Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market witnesses growth driven by key drivers and emerging trends in the healthcare sector. With the increase in incidence and prevalence of ALS, coupled with a significant unmet need for effective treatments, there's heightened research funding directed towards ALS treatment development. Additionally, the aging population contributes to market growth, along with the development of novel drugs specifically targeting ALS. However, challenges such as the high cost of treatment and stringent regulatory guidelines pose hurdles to market expansion, highlighting the need for innovative solutions to address these complexities in the global ALS treatment market.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

The Global Amyotrophic Lateral Sclerosis Treatment Market addresses the urgent need for therapies to combat Lou Gehrig's disease, a form of motor neuron disease characterized by nerve cell degeneration, genetic inheritance, and gene mutation, leading to glutamate accumulation and respiratory failure, affecting both men and women, with medications available through hospital pharmacies.

Market Segmentation

In the intravenous segment of the Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, therapies such as Ursodoxicoltaurine are crucial for managing this neurodegenerative disorder. ALS affects the central nervous system, leading to the progressive degeneration of voluntary muscles. With a growing geriatric population, awareness about ALS and its impact on daily functions such as swallowing, breathing, speaking, walking, and hand movement is increasing. The prevalence of ALS varies, with both sporadic and familial types affecting populations worldwide. Despite advancements in drug therapies, the stationary lifestyle associated with ALS and the high cost of treatment remain significant challenges. Efforts to reduce infection rates and improve access to affordable treatments are essential for addressing the needs of ALS patients globally.

Type Analysis 

The market share by the intravenous segment will be significant during the forecast period. One of the primary factors for the growth of this market is the boost in the majority of amyotrophic lateral sclerosis. Several lateral sclerosis cases are sporadic, and 5%-10% of cases are familial. Every year, approximately 30,000 individuals are diagnosed in the US. Therefore, the increase in the prevalence of amyotrophic lateral sclerosis will boost the growth of the market during the forecast period.

Get a glance at the market contribution of various segments View a PDF Sample

The intravenous segment was valued at USD 333.55 million in 2018. Furthermore, advancements associated with motor neuron disease treatment are modest and are mostly outweighed by the inconvenience associated with receiving infusion therapy to patients who are mostly immobile and are on ventilation. Muscle relaxants and non-invasive ventilation are often utilized in conjunction with intravenous treatments to manage symptoms and improve patient comfort. Hence, these factors will drive the growth of the intravenous segment of the treatment market during the forecast period.

Regional Analysis

For more insights about the market research and growth share of various regions View PDF Sample now!

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The market in North America is driven by the US due to the existence of major market players such as Pfizer, Sangamo Therapeutics, and Celgene in the US and Canada. In addition, these players invest in marketing and patient awareness initiatives. Moreover, the US is anticipated to negatively impact the North American market due to the advanced healthcare infrastructure and availability of therapies for the Market and the high disease prevalence and incidence. Canada is expected to emerge as the second-largest market due to increasing disease prevalence. Hence, such factors are expected to drive market growth in this region during the forecast period.

Buy Now Full Report and Discover More

Market Dynamics and Customer Landscape

The market report witnessed significant attention due to its impact on nerve cells, spinal cord, and associated symptoms like paralysis, stiffness, and twitching. The Difficulty of speaking, swallowing, and breathing underscore the urgency for effective treatments. FDA-approved drugs address symptoms, but side effects such as diarrhea, nausea, and upper respiratory infections pose concerns. With a rising demand for ALS drugs, untapped emerging markets offer growth opportunities supported by improved healthcare expenditure.

Early diagnosis through physical examinations and medical history reviews is crucial, emphasizing the importance of timely intervention. Despite delays and restraints, investments in ALS research and development, along with clinical trials, drive stable growth in the market segments. Rising awareness and evolving trends underscore the estimations for the ALS treatment market's future trajectory. There are multiple factors influencing the market. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Market Drivers

High research funding on the market is the key factor driving market growth. Funding for studies in neurogenerative diseases has been raised. For example, the EU joint program - Neurogenerative Disease Research (JPND), an innovative, collaborative research initiative established to tackle the challenges posed, is funding research scientists to conduct novel approaches that would help enhance the use of brain images for amyotrophic lateral sclerosis. This would cover a range of neurodegenerative diseases, including treatment.

Furthermore, in 2021, Neuratris, a research organization that deals in the research of innovative methods for the treatment of nervous system diseases, launched a new funding program for neurodegenerative diseases, including the Market under which the organization has provided funds worth USD 55,000 to cover the cost of the project. Thus, high research funding on the market will drive the growth of the global Market during the forecast period.

Significant Market Trends

An increase in the aging population is the primary trend shaping market growth. The aging population has been increasing across the globe with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn, raised the risk of developing neurological disorders such as Alzheimer's disease and Parkinson's disease.

Moreover, according to WHO, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. In Sub-Saharan Africa, neurological disorders are commonly found in the elderly; degenerative diseases such as dementia and PD were the most common diseases reported in the region. Therefore, an increase in the aging population will drive the growth of the global Market during the forecast period.

Major Market Challenges

The availability of ineffective diagnosis methods is a challenge that affects market growth. Direct diagnostic tests are not open to select the presence of individuals. Instead, physicians opt to perform a series of tests, which help to distinguish from similar neurological diseases to arrive at an accurate diagnosis for amyotrophic lateral sclerosis. Furthermore, the initial symptoms can vary from person to person.

In addition, initial symptoms and MS are similar and may include muscle weakness, loss of coordination, and difficulty in moving limbs. Both diseases affect muscle and nerve function. It is difficult to analyze whether the symptoms are due to MS or amyotrophic lateral sclerosis. Thus, these factors are expected to restrain the growth of the global market during the forecast period.

Buy Now Full Report and Discover More

Customer Landscape

The market growth and forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and trends report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth market forecasting strategies.

Global Market Customer Landscape

Market Analyst Overview

The Amyotrophic Lateral Sclerosis (ALS) treatment market is focused on combating this progressive neurodegenerative disease through various therapeutic approaches. ALS therapy aims to alleviate symptoms, slow disease progression, and improve the quality of life for patients. Current ALS treatments include medications like Riluzole and Edaravone, which have shown efficacy in delaying disease progression. Additionally, stem cell therapy holds promise for regenerative treatment options.

The market faces significant challenges despite advancements in Medical technology. While Stem cell therapies hold promise, there is less awareness and insubstantial treatment options available, leading to limited options for patients. Immunosuppressants are often used to manage symptoms, highlighting the need for more effective solutions. The reimbursement scenario further complicates access to care. Organizations like the Centers for Disease Control and Prevention (CDC) play a crucial role in raising awareness. Pharmaceutical companies like NeuroSense Therapeutics drive innovation, often supported by seed funding. Genetics and biomarkers are increasingly studied to understand the disease better and develop targeted therapies.

The market addresses the urgent need for effective therapies to combat this neurodegenerative disorder, characterized by Lou Gehrig's disease, genetic inheritance, gene mutation, glutamate, and respiratory failure, impacting women and the geriatric population, with drug therapies available through online providers, Drug stores & retail pharmacies, particularly crucial for addressing the prevalence of ALS disease and awareness about ALS disease and its incidence rates, considering its sporadic type and familial types, while also focusing on the ability to swallow, breathe, speak, walk, and use hands, in the face of the challenges posed by stationary lifestyle and expensive treatment.

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Denali Therapeutics Inc.: The company offers to slow disease progression, including advancing clinical trials of investigational eIF2B activator treatment DNL343.

• AB Science SA
• Alkem Laboratories Ltd.
• Apotex Inc.
• Aquestive Therapeutics Inc.
• Biogen Inc.
• Brainstorm Cell Therapeutics Inc.
• CORESTEM Inc.
• Cytokinetics Inc.
• Dr Reddys Laboratories Ltd.
• Eledon Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Italfarmaco Holding SPA
• Medindia Health
• Mitsubishi Chemical Group Corp.
• Otsuka Holdings Co. Ltd.
• Revalesio Corp.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Treeway BV

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market analysis and report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and opportunities from 2018 to 2028. 

• Type Outlook
  • Intravenous
  • Oral

• Distribution Channel Outlook 
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of the World (ROW)
    • Argentina
    • Australia
    • Brazil

Amyotrophic Lateral Sclerosis Treatment Market Scope
Report Coverage	Details
Page number	157
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 12.79%
Market growth 2024-2028	USD 663.7 million
Market structure	Fragmented
YoY growth 2023-2024(%)	12.48
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 42%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	AB Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc., Biogen Inc., Brainstorm Cell Therapeutics Inc., CORESTEM Inc., Cytokinetics Inc., Denali Therapeutics Inc., Dr Reddys Laboratories Ltd., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi, Sun Pharmaceutical Industries Ltd., and Treeway BV
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market between 2024 and 2028
• Precise estimation of the market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
• Market growth analysis across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch